Reversal agents for direct oral anticoagulants

Kelly Rogers, Melanie P. Shelton, Shannon Finks

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Direct oral anticoagulants (DOACs), originally developed as an alternative for vitamin K antagonists, are shifting the landscape of antithrombotic therapy. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban offer enhancements in safety, convenience, and efficacy compared with warfarin. However, as choices for oral anticoagulation therapy have increased, so has the need for effectual antidotes before urgent surgical procedures and for the reversal of serious adverse events caused by DOACs. To date, one antidote has been FDA approved in the United States for the reversal of dabigatran, and two antidotes are undergoing phase 2and 3clinical trials. This review will summarize currently available and developing data for DOAC antidotes: idarucizumab, exanet alfa, and ciraparantag.

Original languageEnglish (US)
Pages (from-to)310-315
Number of pages6
JournalCardiology in review
Volume24
Issue number6
DOIs
StatePublished - Jan 1 2016

Fingerprint

Antidotes
Anticoagulants
Vitamin K
Warfarin
Safety
Therapeutics
Dabigatran

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Reversal agents for direct oral anticoagulants. / Rogers, Kelly; Shelton, Melanie P.; Finks, Shannon.

In: Cardiology in review, Vol. 24, No. 6, 01.01.2016, p. 310-315.

Research output: Contribution to journalReview article

Rogers, Kelly ; Shelton, Melanie P. ; Finks, Shannon. / Reversal agents for direct oral anticoagulants. In: Cardiology in review. 2016 ; Vol. 24, No. 6. pp. 310-315.
@article{a9f2c24df1064168b091c13825fbef14,
title = "Reversal agents for direct oral anticoagulants",
abstract = "Direct oral anticoagulants (DOACs), originally developed as an alternative for vitamin K antagonists, are shifting the landscape of antithrombotic therapy. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban offer enhancements in safety, convenience, and efficacy compared with warfarin. However, as choices for oral anticoagulation therapy have increased, so has the need for effectual antidotes before urgent surgical procedures and for the reversal of serious adverse events caused by DOACs. To date, one antidote has been FDA approved in the United States for the reversal of dabigatran, and two antidotes are undergoing phase 2and 3clinical trials. This review will summarize currently available and developing data for DOAC antidotes: idarucizumab, exanet alfa, and ciraparantag.",
author = "Kelly Rogers and Shelton, {Melanie P.} and Shannon Finks",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/CRD.0000000000000118",
language = "English (US)",
volume = "24",
pages = "310--315",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Reversal agents for direct oral anticoagulants

AU - Rogers, Kelly

AU - Shelton, Melanie P.

AU - Finks, Shannon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Direct oral anticoagulants (DOACs), originally developed as an alternative for vitamin K antagonists, are shifting the landscape of antithrombotic therapy. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban offer enhancements in safety, convenience, and efficacy compared with warfarin. However, as choices for oral anticoagulation therapy have increased, so has the need for effectual antidotes before urgent surgical procedures and for the reversal of serious adverse events caused by DOACs. To date, one antidote has been FDA approved in the United States for the reversal of dabigatran, and two antidotes are undergoing phase 2and 3clinical trials. This review will summarize currently available and developing data for DOAC antidotes: idarucizumab, exanet alfa, and ciraparantag.

AB - Direct oral anticoagulants (DOACs), originally developed as an alternative for vitamin K antagonists, are shifting the landscape of antithrombotic therapy. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban offer enhancements in safety, convenience, and efficacy compared with warfarin. However, as choices for oral anticoagulation therapy have increased, so has the need for effectual antidotes before urgent surgical procedures and for the reversal of serious adverse events caused by DOACs. To date, one antidote has been FDA approved in the United States for the reversal of dabigatran, and two antidotes are undergoing phase 2and 3clinical trials. This review will summarize currently available and developing data for DOAC antidotes: idarucizumab, exanet alfa, and ciraparantag.

UR - http://www.scopus.com/inward/record.url?scp=84983349748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983349748&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000118

DO - 10.1097/CRD.0000000000000118

M3 - Review article

VL - 24

SP - 310

EP - 315

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 6

ER -